Search results
Results from the WOW.Com Content Network
[215] [216] [217] Accordingly, progestogens, both endogenous and exogenous (i.e., progestins), have antigonadotropic effects, [218] and progestogens in sufficiently high amounts can markedly suppress the body's normal production of progestogens, androgens, and estrogens as well as inhibit fertility (ovulation in women and spermatogenesis in men).
Depo-Provera, Depo-SubQ Provera 104, others: AHFS/Drugs.com: depo-provera: Failure rates (first year) Perfect use: 0.2% [37] Typical use: 6% [37] Usage; Duration effect: 3 months (12–14 weeks) Reversibility: 3–18 months: User reminders: Maximum interval is just under 3 months: Clinic review: 12 weeks: Advantages and disadvantages; STI ...
Androgen therapy can cause weight gain and decreased insulin sensitivity (perhaps worsening a predisposition to develop Type II diabetes). Androgen therapy effects are not all negative, however. Acutely it causes dilation of the coronary arteries, and in men with testosterone levels within the normal physiological range, higher levels are ...
Depo Provera, the shot: 4 (1 in 25) 0.2 (1 in 500) Progestogen: Injection: 12 weeks: Testosterone injection for male (unapproved, experimental method) [39] Testosterone Undecanoate: 6.1 (1 in 16) 1.1 (1 in 91) Testosterone: Intramuscular Injection: Every 4 weeks: 1999 cervical cap and spermicide (replaced by second generation in 2003) [40] FemCap
Medroxyprogesterone acetate (brand names Depo-Provera, Provera, Depo-subQ Provera 104) [4] – 150 mg (intramuscularly) or 104 mg (subcutaneously) every 3 months [3] Norethisterone enanthate (brand names NET EN, Noristerat, Norigest, Doryxas) [5] – 200 mg (intramuscularly) every 2 months [3]
Depot MPA (DMPA) and EC/MPA were developed by Upjohn in the 1960s. [12] [13] DMPA (brand name Depo-Provera) was introduced for use as a progestogen-only injectable contraceptive for the first time outside of the United States in 1969 and was subsequently approved for use in birth control in the United States in 1992.
Research conducted by Indiana University's Center for Sexual Health showed that using lube makes it 50% easier for both men and women to orgasm. And it makes sense, too: according to Elist, lube ...
In 1957 Enovid, the first COCP, was approved in the United States for the treatment of menstrual disorders. In 1960, the U.S. Food and Drug Administration approved an application that allowed Enovid to be marketed as a contraceptive. [53] The first progestogen-only contraceptive was introduced in 1969: Depo-Provera, a high-dose progestin ...